Ashton Thomas Securities’s Biogen BIIB Stock Holding History

Ashton Thomas Securities’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-171	Closed	-$33.1K	–	354
2024 Q3	$33.1K	Buy	+171	New	+$35.8K	0.01%	506

Other funds holding BIIB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Ashton Thomas Securities's BIIB Position: Q4 2024 in Review

Ashton Thomas Securities sold out of Biogen (BIIB) in Q4 2024, closing a stake of 171 shares — an estimated $33.1K sold.

Ashton Thomas Securities first reported a position in BIIB in Q3 2024 and held it in 1 quarter. The position peaked at $33.1K in Q3 2024. 876 funds tracked by Wall St. Rank hold BIIB as of Q4 2024.

Ashton Thomas Securities reported no remaining Biogen position as of Q4 2024 after selling out during the quarter.
Ashton Thomas Securities sold 171 Biogen shares in Q4 2024, an estimated $33.1K.
Ashton Thomas Securities first reported a position in Biogen in Q3 2024 and held it in 1 quarter.
Ashton Thomas Securities's Biogen position peaked at $33.1K in Q3 2024.
876 funds tracked by Wall St. Rank held Biogen as of Q4 2024.

Based on Ashton Thomas Securities's 13F filing for Q4 2024, filed 11 Feb 2025.